Low Primary and Secondary HIV Drug-Resistance after 12 Months of Antiretroviral Therapy in Human Immune-Deficiency Virus Type 1 (HIV-1)-Infected Individuals from Kigali, Rwanda

John Rusine; Brenda Asiimwe-Kateera; Janneke van de Wijgert; Kimberly Rachel Boer; Enatha Mukantwali; Etienne Karita; Agnes Gasengayire; Suzanne Jurriaans; Menno de Jong; Pascale Ondoa

doi:10.1371/journal.pone.0064345

Loading metrics

Open Access

Peer-reviewed

Research Article

Low Primary and Secondary HIV Drug-Resistance after 12 Months of Antiretroviral Therapy in Human Immune-Deficiency Virus Type 1 (HIV-1)-Infected Individuals from Kigali, Rwanda

John Rusine,

Affiliations Amsterdam Institute for Global Health and Development (AIGHD), Department of Global Health, Academic Medical Center, Amsterdam, The Netherlands, National Reference Laboratory, Kigali, Rwanda, The Infectious Diseases Network for Treatment and Research in Africa (INTERACT) project, Kigali, Rwanda
⨯
Brenda Asiimwe-Kateera,

Affiliations Amsterdam Institute for Global Health and Development (AIGHD), Department of Global Health, Academic Medical Center, Amsterdam, The Netherlands, The Infectious Diseases Network for Treatment and Research in Africa (INTERACT) project, Kigali, Rwanda
⨯
Janneke van de Wijgert,

Affiliations Amsterdam Institute for Global Health and Development (AIGHD), Department of Global Health, Academic Medical Center, Amsterdam, The Netherlands, University of Liverpool, Institute of Infection and Global Health, Liverpool, United Kingdom
⨯
Kimberly Rachel Boer,

Affiliations Amsterdam Institute for Global Health and Development (AIGHD), Department of Global Health, Academic Medical Center, Amsterdam, The Netherlands, Royal Tropical Institute, Biomedical Research, Amsterdam, The Netherlands, The Infectious Diseases Network for Treatment and Research in Africa (INTERACT) project, Kigali, Rwanda
⨯
Enatha Mukantwali,

Affiliation National Reference Laboratory, Kigali, Rwanda
⨯
Etienne Karita,

Affiliation Project San Francisco, Kigali, Rwanda
⨯
Agnes Gasengayire,

Affiliation National Reference Laboratory, Kigali, Rwanda
⨯
Suzanne Jurriaans,

Affiliation Academic Medical Center, Department of Medical Microbiology, Amsterdam, The Netherlands
⨯
Menno de Jong,

Affiliation Academic Medical Center, Department of Medical Microbiology, Amsterdam, The Netherlands
⨯
Pascale Ondoa

* E-mail: p.ondoa@aighd.org

Affiliation Amsterdam Institute for Global Health and Development (AIGHD), Department of Global Health, Academic Medical Center, Amsterdam, The Netherlands
⨯

Low Primary and Secondary HIV Drug-Resistance after 12 Months of Antiretroviral Therapy in Human Immune-Deficiency Virus Type 1 (HIV-1)-Infected Individuals from Kigali, Rwanda

John Rusine,
Brenda Asiimwe-Kateera,
Janneke van de Wijgert,
Kimberly Rachel Boer,
Enatha Mukantwali,
Etienne Karita,
Agnes Gasengayire,
Suzanne Jurriaans,
Menno de Jong,
Pascale Ondoa

Published: August 12, 2013
https://doi.org/10.1371/journal.pone.0064345

Reader Comments (0)

Post a new comment on this article

Subject Areas
?

For more information about PLOS Subject Areas, click here.
We want your feedback. Do these Subject Areas make sense for this article? Click the target next to the incorrect Subject Area and let us know. Thanks for your help!

HIV
Is the Subject Area "HIV" applicable to this article?

Thanks for your feedback.
Antiretroviral therapy
Is the Subject Area "Antiretroviral therapy" applicable to this article?

Thanks for your feedback.
Viral load
Is the Subject Area "Viral load" applicable to this article?

Thanks for your feedback.
Genotyping
Is the Subject Area "Genotyping" applicable to this article?

Thanks for your feedback.
HIV-1
Is the Subject Area "HIV-1" applicable to this article?

Thanks for your feedback.
Rwanda
Is the Subject Area "Rwanda" applicable to this article?

Thanks for your feedback.
Virus testing
Is the Subject Area "Virus testing" applicable to this article?

Thanks for your feedback.
Therapeutic drug monitoring
Is the Subject Area "Therapeutic drug monitoring" applicable to this article?

Thanks for your feedback.